Fig. 2From: Cost-effectiveness of dexamethasone compared with aflibercept in naïve diabetic macular edemaAflibercept (red). Dexamethasone (blue). Acceptability curve obtained with probabilistic sensitivity analysis in the lifetime horizon. Below the 30.000 €/QALY, dexamethasone is the therapy of choice in 54% of casesBack to article page